BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28681313)

  • 1. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
    Wang Y; He L; Cheng Y
    Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
    Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
    Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
    Dang HZ; Yu Y; Jiao SC
    World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular biology and immunohistochemical studies of Her2/neu oncogene in stomach cancer].
    Jähne J; Urmacher C; Albino A; Meyer HJ; Pichlmayr R
    Chirurg; 1994 Apr; 65(4):307-11. PubMed ID: 7912666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.
    Li X; Zhao H; Gu J; Zheng L
    World J Surg Oncol; 2016 Feb; 14(1):38. PubMed ID: 26897036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
    Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
    World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
    Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
    Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis.
    Chen C; Yang JM; Hu TT; Xu TJ; Yan G; Hu SL; Wei W; Xu WP
    Arch Med Res; 2013 Jul; 44(5):380-9. PubMed ID: 23871709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFF3 and HER2 expression and their correlation with survival in gastric cancer.
    Gu J; Zheng L; Zhang L; Chen S; Zhu M; Li X; Wang Y
    Tumour Biol; 2015 Apr; 36(4):3001-7. PubMed ID: 25514872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
    Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
    World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis.
    Qian H; Appiah-Kubi K; Wang Y; Wu M; Tao Y; Wu Y; Chen Y
    Crit Rev Oncol Hematol; 2018 Jul; 127():15-28. PubMed ID: 29891108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.
    Subasinghe D; Sivaganesh S; Samarsekera A; Kumarasinghe MP; Samarasekera DN; Lokuhetty MDS
    Dig Dis Sci; 2017 Sep; 62(9):2498-2510. PubMed ID: 28612195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.
    Kim H; Seo S; Kim K; Park YH; An M; Baik H; Choi C; Oh S
    World J Surg Oncol; 2019 Jul; 17(1):122. PubMed ID: 31296222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.